Leerink cuts target for Bristol Myers Squibb stock to USD 59.00

Published on 10/07/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CAMZYOS won pediatric approval on September 30, 2026. Bristol Myers Squibb stock costs EUR 52.90 on October 7, 2026 versus EUR 52.90.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) was trading at EUR 52.90 at Lang & Schwarz on October 7, 2026 at 3:39 p.m. CEST, unchanged from the prior close of EUR 52.90. The latest market signal came on October 5, 2026, when Leerink Partners cut its target from USD 73.00 to USD 59.00 and downgraded the stock from Outperform to Market Perform, MarketBeat reported.

Leerink resets the valuation bar

The USD 14.00 reduction puts the new target below the latest U.S. market reference cited by MarketBeat. For investors, the change shifts attention from Bristol Myers Squibb's recent earnings delivery to the timing and commercial strength of its pipeline replacements.

The Globe and Mail also listed the Leerink action on October 5, 2026, confirming the move from Outperform to Market Perform and the target change from USD 73.00 to USD 59.00.

Quarterly figures offer a counterweight

In the latest quarterly results released on July 30, 2026, Bristol Myers Squibb reported USD 12.97 billion in revenue against a USD 11.74 billion estimate, according to MarketBeat. Revenue increased 5.70 percent year over year, while earnings per share reached USD 2.04 against consensus of USD 1.60.

The company set fiscal 2026 earnings-per-share guidance at USD 6.75-7.00 in the same report. That combination of revenue growth and guidance gives the stock a fundamental support point, while the analyst downgrade highlights execution risk around future medicines.

CAMZYOS expands the growth portfolio

On September 30, 2026, the U.S. Food and Drug Administration approved CAMZYOS for symptomatic obstructive hypertrophic cardiomyopathy in adults and eligible pediatric patients weighing at least 30 kilograms, according to Bristol Myers Squibb. The SCOUT-HCM trial enrolled 44 adolescent patients, with 23 receiving CAMZYOS and 21 receiving placebo.

The approval broadens a cardiovascular product's addressable population, but the company states that CAMZYOS carries a boxed warning for heart failure and requires echocardiogram monitoring. That safety framework remains an important commercial consideration alongside the new pediatric indication.

Results date gives the next checkpoint

Bristol Myers Squibb will report third-quarter 2026 results on October 29, 2026, with the conference call scheduled for 8:00 a.m. ET, according to Bristol Myers Squibb. The report will test whether the 5.70 percent year-over-year revenue growth from the latest quarter can continue while pipeline concerns remain part of the valuation debate.

Stock holds at the prior close

Bristol Myers Squibb was trading at EUR 52.90 at Lang & Schwarz on October 7, 2026 at 3:39 p.m. CEST, plus or minus 0.00 percent versus the Lang & Schwarz prior close of EUR 52.90 on October 6, 2026. On the NYSE, the primary listing is quoted in USD; the finance quote showed a market capitalization of USD 121.7 billion and a 52-week range of USD 42.52 to USD 68.64 as of October 7, 2026.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.